Clinical review evaluates enlicitide decanoate for lipid lowering in hypercholesterolemia, suggesting oral PCSK9 inhibition may improve treatment adherence over injectable options.
Key Points
To review the pharmacology, efficacy, safety, and clinical positioning of enlicitide decanoate, the first oral PCSK9 inhibitor for hypercholesterolemia.
Synthesized pharmacological profiles and trial evidence from the phase 2 and phase 3 CORALreef clinical trial program.
Evaluated outcomes across patient populations with hypercholesterolemia, heterozygous familial hypercholesterolemia, and established or high risk for atherosclerotic cardiovascular disease.
Compared enlicitide data against existing lipid-lowering therapies, including statins, ezetimibe, and approved injectable PCSK9 inhibitors.
Enlicitide decanoate demonstrated effective reduction of low-density lipoprotein cholesterol across phase 2 and phase 3 clinical trials.
Oral administration provides an alternative to subcutaneous injections, potentially improving patient accessibility and long-term treatment adherence.
Definitive adoption will depend on upcoming cardiovascular outcomes data, long-term safety profiles, and cost-effectiveness relative to established injectable agents.